Filters
clear all
Filters
Brand
Type
Topics
Markets
Mitchell Article

The Long, Winding Road of Drug Pricing

April 10, 2022

One of the most persistent and complex challenges facing workers’ compensation claims administrators and insurers is managing prescription drug costs. The problems around prescription drugs are pervasive throughout the health care industry, have been around for over a century, and cover a wide range of issues including accessibility, efficacy and cost. For workers’ compensation payors, cost has been the most challenging issue. 

Enlyte Article

Top Auto Casualty Trends to Watch in 2022

January 27, 2022

The year 2021 brought new challenges to the auto insurance industry—from frequent shifts in miles driven to significant staffing shortages. As we enter 2022, insurance carriers will need to manage many of these trends expected to continue. To help you prepare and navigate what’s next, here are Enlyte’s top 2022 predictions:

Enlyte Article

Workers’ Compensation: 2022 Trends & Predictions

January 27, 2022

As we enter 2022 still mired in the COVID-19 pandemic, the workers’ compensation industry faces another challenging year, with payers continuing to cope with staffing shortages, evolving regulatory changes and more. To help you navigate what’s next and understand this year’s top trends, we’ve outlined Enlyte’s top 2022 workers’ compensation predictions:

Enlyte Article

P&C Industry Claims Severity: Trends, Drivers and Mitigators

January 25, 2022

Claim severity has always been top of mind for the P&C industry. While the pandemic has certainly had an impact on claims costs, there are several drivers behind claim severity trends varying by market. While it is important to note what is behind claims costs, it is equally important to understand how to mitigate severity and control costs.

Mitchell Article

Release of Generic Medications for Workers' Comp in 2022

November 15, 2021

Next year twenty-eight drugs relevant to workers’ compensation are expected to become available as generics. These formulations will be made available once the original drug manufacturer’s brand name period of exclusivity has expired.

Mitchell Article

FDA Approves Combination NSAID/Opioid Seglentis

October 21, 2021

On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Mitchell Article

Opioid Reduction Success

September 28, 2021